Bridge Pharmaceuticals' China Facility Receives Full AAALAC Accreditation
First Preclinical CRO with US and China Multispecies Capabilities
Bridge Pharmaceuticals, Inc. announced the awarding of full accreditation to its facility in Beijing, China by the Council on Accreditation of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC International).
Bridge's facility in Beijing (Vital Bridge (China), Inc.) is one of only seven toxicology facilities in China to receive this recognition, and Bridge is the first US-based company to offer toxicology services in multispecies at both locations in the US and China. In the accreditation letter to Bridge dated June 28, 2007, AAALAC International states, "The management and staff are commended for providing quality facilities and programs for the care and use of laboratory animals. Especially noteworthy were the institution's strong administrative support for the animal care and use program as exemplified by the high quality facilities, the extensive investment in training and education of personnel, and the excellent teamwork noted among the staff (at Bridge); as well as the extensive, well conceived, and thoroughly implemented occupational health and safety program."
Other news from the department politics & laws
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
